Published in Clin Cancer Res on March 15, 2008
Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer. Br J Cancer (2010) 1.96
Characterization of the intestinal cancer stem cell marker CD166 in the human and mouse gastrointestinal tract. Gastroenterology (2010) 1.86
Oncologic trogocytosis of an original stromal cells induces chemoresistance of ovarian tumours. PLoS One (2008) 1.17
Increased expression of ALCAM/CD166 in pancreatic cancer is an independent prognostic marker for poor survival and early tumour relapse. Br J Cancer (2009) 1.16
Identification of CD166 as a surface marker for enriching prostate stem/progenitor and cancer initiating cells. PLoS One (2012) 1.04
Gene expression profiles in stage I uterine serous carcinoma in comparison to grade 3 and grade 1 stage I endometrioid adenocarcinoma. PLoS One (2011) 0.98
A seven-gene prognostic model for platinum-treated ovarian carcinomas. Br J Cancer (2011) 0.96
Plasma membrane proteomics of tumor spheres identify CD166 as a novel marker for cancer stem-like cells in head and neck squamous cell carcinoma. Mol Cell Proteomics (2013) 0.95
CD166/activated leukocyte cell adhesion molecule is expressed on glioblastoma progenitor cells and involved in the regulation of tumor cell invasion. Neuro Oncol (2011) 0.94
Elevated ALCAM shedding in colorectal cancer correlates with poor patient outcome. Cancer Res (2013) 0.91
ALCAM/CD166 is a TGF-β-responsive marker and functional regulator of prostate cancer metastasis to bone. Cancer Res (2014) 0.90
A novel human recombinant single-chain antibody targeting CD166/ALCAM inhibits cancer cell invasion in vitro and in vivo tumour growth. Cancer Immunol Immunother (2010) 0.90
An engineered cysteine-modified diabody for imaging activated leukocyte cell adhesion molecule (ALCAM)-positive tumors. Mol Imaging Biol (2012) 0.90
ALCAM (CD166) expression and serum levels in pancreatic cancer. PLoS One (2012) 0.89
Enhanced immunoPET of ALCAM-positive colorectal carcinoma using site-specific ⁶⁴Cu-DOTA conjugation. Protein Eng Des Sel (2014) 0.87
Prognostic value of CD166 expression in cancers of the digestive system: a systematic review and meta-analysis. PLoS One (2013) 0.85
Relevance of activated leukocyte cell adhesion molecule (ALCAM) in tumor tissue and sera of cervical cancer patients. BMC Cancer (2012) 0.84
ALCAM: Basis Sequence: Mouse. AFCS Nat Mol Pages (2015) 0.81
P21 and CD166 as predictive markers of poor response and outcome after fluorouracil-based chemoradiotherapy for the patients with rectal cancer. BMC Cancer (2014) 0.81
Activated leukocyte cell adhesion molecule expression and shedding in thyroid tumors. PLoS One (2011) 0.79
Lesser-Known Molecules in Ovarian Carcinogenesis. Biomed Res Int (2015) 0.78
Clinicopathological significance of cancer stem-like cell markers in high-grade neuroendocrine carcinoma of the lung. J Cancer Res Clin Oncol (2015) 0.76
Cell Adhesion Molecules and Ubiquitination-Functions and Significance. Biology (Basel) (2015) 0.75
Activated Leukocyte Cell Adhesion Molecule (ALCAM) in Saudi Breast Cancer Patients as Prognostic and Predictive Indicator. Breast Cancer (Auckl) (2015) 0.75
Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res (2005) 11.52
Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature (2004) 8.35
Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res (2005) 7.66
A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res (2006) 7.09
A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer. Nat Genet (2005) 6.70
High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol (2006) 5.86
Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res (2005) 5.70
Quantification of free circulating DNA as a diagnostic marker in lung cancer. J Clin Oncol (2003) 4.22
A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology (2004) 3.61
Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol (2007) 3.38
Limits of predictive models using microarray data for breast cancer clinical treatment outcome. J Natl Cancer Inst (2005) 3.26
Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. BMC Genomics (2008) 3.24
Malignant peripheral nerve sheath tumors: prognostic factors and survival in a series of patients treated at a single institution. Cancer (2006) 2.98
Academic output of 9 years of EU investment into health research. Lancet (2012) 2.47
CD3+ cells at the invasive margin of deeply invading (pT3-T4) colorectal cancer and risk of post-surgical metastasis: a longitudinal study. Lancet Oncol (2009) 2.47
Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell (2013) 2.35
Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST. Ann Surg (2007) 2.30
Cell membrane reactivity of MIB-1 antibody to Ki67 in human tumors: fact or artifact? Appl Immunohistochem Mol Morphol (2007) 2.21
SMARCB1/INI1 tumor suppressor gene is frequently inactivated in epithelioid sarcomas. Cancer Res (2005) 2.20
Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. Clin Cancer Res (2004) 2.17
Alterations of choline phospholipid metabolism in ovarian tumor progression. Cancer Res (2005) 2.11
Human cutaneous melanomas lacking MITF and melanocyte differentiation antigens express a functional Axl receptor kinase. J Invest Dermatol (2011) 2.09
Axillary lymph node dissection versus no dissection in patients with T1N0 breast cancer: a randomized clinical trial (INT09/98). Cancer (2013) 2.07
The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma. J Hepatol (2008) 2.03
Different genetic features associated with colon and rectal carcinogenesis. Clin Cancer Res (2004) 1.99
30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. BMJ (2005) 1.97
Imatinib mesylate in chordoma. Cancer (2004) 1.94
TP53 mutations and pathologic complete response to neoadjuvant cisplatin and fluorouracil chemotherapy in resected oral cavity squamous cell carcinoma. J Clin Oncol (2010) 1.93
Phase II study of imatinib in advanced chordoma. J Clin Oncol (2012) 1.89
MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents. Proc Natl Acad Sci U S A (2006) 1.82
Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene (2004) 1.82
Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene. Proc Natl Acad Sci U S A (2005) 1.70
Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. Cancer Res (2010) 1.68
Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix. Blood (2002) 1.66
PDGFRA immunostaining can help in the diagnosis of gastrointestinal stromal tumors. Am J Surg Pathol (2008) 1.65
Activation of phosphatidylcholine cycle enzymes in human epithelial ovarian cancer cells. Cancer Res (2010) 1.65
Chromosome band 17q21 in breast cancer: significant association between beclin 1 loss and HER2/NEU amplification. Genes Chromosomes Cancer (2010) 1.63
HER2 overexpression and doxorubicin in adjuvant chemotherapy for resectable breast cancer. J Clin Oncol (2003) 1.61
A randomized trial comparing axillary dissection to no axillary dissection in older patients with T1N0 breast cancer: results after 5 years of follow-up. Ann Surg (2005) 1.60
BRAF alterations are associated with complex mutational profiles in malignant melanoma. Oncogene (2004) 1.58
IL-21 induces tumor rejection by specific CTL and IFN-gamma-dependent CXC chemokines in syngeneic mice. J Immunol (2004) 1.58
Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients. J Neurol Neurosurg Psychiatry (2013) 1.55
Hysteroscopic injection of tracers in sentinel node detection of endometrial cancer: a feasibility study. Am J Obstet Gynecol (2004) 1.55
RET and NTRK1 proto-oncogenes in human diseases. J Cell Physiol (2003) 1.55
Surgical treatment of giant pituitary adenomas: strategies and results in a series of 95 consecutive patients. Neurosurgery (2007) 1.52
Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors. Mol Cancer Ther (2009) 1.52
Challenges in projecting clustering results across gene expression-profiling datasets. J Natl Cancer Inst (2007) 1.52
Impact of biospecimens handling on biomarker research in breast cancer. BMC Cancer (2009) 1.51
The use of a tropism-modified measles virus in folate receptor-targeted virotherapy of ovarian cancer. Clin Cancer Res (2006) 1.50
Chemotherapy-Induced Peripheral Neurotoxicity assessment: a critical revision of the currently available tools. Eur J Cancer (2010) 1.50
KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors. Clin Cancer Res (2012) 1.49
Cutaneous melanoma in childhood and adolescence shows frequent loss of INK4A and gain of KIT. J Invest Dermatol (2009) 1.48
Evaluation of SNPs in miR-146a, miR196a2 and miR-499 as low-penetrance alleles in German and Italian familial breast cancer cases. Hum Mutat (2010) 1.45
Telomere maintenance mechanisms in liposarcomas: association with histologic subtypes and disease progression. Cancer Res (2006) 1.44
Role of microRNAs in ovarian cancer pathogenesis and potential clinical implications. Int J Biochem Cell Biol (2009) 1.43
Cancer stem cells: a new paradigm for understanding tumor growth and progression and drug resistance. Curr Med Chem (2009) 1.41
Lack of SYT-SSX fusion transcripts in malignant peripheral nerve sheath tumors on RT-PCR analysis of 34 archival cases. Lab Invest (2002) 1.40
Detection of post-exercise stunning by early gated SPECT myocardial perfusion imaging: results from the IAEA multi-center study. J Nucl Cardiol (2014) 1.39
Response to sunitinib malate in advanced alveolar soft part sarcoma. Clin Cancer Res (2009) 1.39
The involvement of the transcription factor Yin Yang 1 in cancer development and progression. Cell Cycle (2009) 1.38
Phosphatase protein homologue to tensin expression and phosphatidylinositol-3 phosphate kinase mutations in colorectal cancer. Cancer Res (2005) 1.38
miRNA profiling in colorectal cancer highlights miR-1 involvement in MET-dependent proliferation. Mol Cancer Res (2012) 1.38
M-CAM expression as marker of poor prognosis in epithelial ovarian cancer. Int J Cancer (2006) 1.38
Unusual myogenic and melanocytic differentiation of soft tissue pPNETs: an immunohistochemical and molecular study of 3 cases. Am J Surg Pathol (2010) 1.38
Interleukin-21 receptor (IL-21R) is up-regulated by CD40 triggering and mediates proapoptotic signals in chronic lymphocytic leukemia B cells. Blood (2006) 1.38
CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction. Int J Cancer (2005) 1.38
Italian performance in cancer research. Tumori (2009) 1.38
Molecular and cytogenetic subgroups of oropharyngeal squamous cell carcinoma. Clin Cancer Res (2006) 1.37
Molecular and biochemical analyses of platelet-derived growth factor receptor (PDGFR) B, PDGFRA, and KIT receptors in chordomas. Clin Cancer Res (2006) 1.35
Inflammation and cancer: the oncogene-driven connection. Cancer Lett (2008) 1.34
Class prediction for high-dimensional class-imbalanced data. BMC Bioinformatics (2010) 1.34
MiR-506 inhibits multiple targets in the epithelial-to-mesenchymal transition network and is associated with good prognosis in epithelial ovarian cancer. J Pathol (2014) 1.33